ArticleLipids in health and disease2025
TNFα activation of the PLEKHA5-FCRLA axis disturbs lipid metabolism, leading to the progression of cutaneous malignant melanoma.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic reprogramming as a driver of immune escape in melanoma: implications for immunotherapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCutaneous malignant melanoma (CMM) ranks among the deadliest forms of cancer. Abnormalities in lipid metabolism may have a connection with the risk of CMM progression.
methodsLipid metabolism-related genes were selected in MSigDB. A lipid metabolism-related predictive model was constructed in The Cancer Genome Atlas-skin cutaneous melanoma (TCGA-SKCM) using univariate Cox regression analysis, non-negative matrix factorization (NMF) clustering analysis, Weighted correlation network analysis (WGCNA), least absolute shrinkage and selection operator regression (LASSO) analysis, and outcomes-related genes were identified. The roles of candidate genes in CMM were determined using in vivo and in vitro experiments, and the pathway mechanism of the candidate gene was studied using transcriptomics, proteomics, lipid metabolomics, and other molecular biological methods.
resultsA predictive model was established, Risk Score = -0.009 * UBE2L6 + 0.033 * PLEKHA5 + 0.024 * LHB + 0.036 * CARM1 + 0.016 * PRXL2B + 0.131 * PLA2G4D. The pleckstrin homology domain-containing A5 (PLEKHA5) was identified as an essential gene and positively correlated with poor outcomes in CMM. Fc receptor-like A (FCRLA) is the downstream gene of PLEKHA5, upregulated in CMM, and tumor necrosis factor alpha (TNFα) is also an essential cytokine that promotes CMM proliferation and metastasis. Lipid metabolomics showed that PLEKHA5 knockdown increased ceramide and sphingosine levels while decreasing cholesterol ester and triglyceride levels in CMM cells, possibly related to disease progression.
conclusionThe predictive model of CMM related to lipid metabolism was constructed. TNFα activates the PLEKHA5-FCRLA axis to enhance neutral lipid storage and energy metabolism in CMM cells, promoting malignant behavior.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.